 |
|
|
| |
ISLATRAVIR (ISL, MK-8591) SAFETY ANALYSIS THROUGH WEEK 48 FROM A PHASE 2 TRIAL IN TREATMENT NAÏVE ADULTS WITH HIV-1 INFECTION
|
| |
| |
Presented at the 23rdInternational AIDS Conference; San Francisco & Oakland, California, USA
https://go.aws/2Ak3eKp
Reported by Jules Levin
July 06-10, 2020
E. DeJesus1, J.-M. Molina2, Y. Yazdanpanah3, A. AfaniSaud4, C. Bettacchi5, C. Chahin Anania6, S.O. Klopfer7, A Grandhi7,
K. Eves7, M.N. Robertson7, P. Sklar7, C. Hwang7, G.J. Hanna7, T. Correll7
1Orlando Immunology Center, Orlando, United States, 2St-Louis Hospital and University, Department of Infectious Disease, Paris, France, 3Bichat Hospital, Paris, France, 4University of Chile, Santiago, Chile, 5North Texas Infectious Diseases Consultants, Dallas, Texas, 6Hospital HernánHenrĂquezAravenaof Temuco, Temuco, Chile, 7Merck & Co., Inc., Kenilworth, NJ, USA
DeJesus IAC 2020
|
| |
|
|
|
|
|
